Kunyang Wu

Kunyang Wu

Auto-generated profile, based on publicly available information

Kunyang Wu

Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ETEnyu Tong
Enyu Tong
QWQian Wu
Qian Wu
YCYiming Chen
Yiming Chen
ZLZhengwei Liu
Zhengwei Liu
MZMingwu Zhang
Mingwu Zhang
JJJianmin Jiang
Jianmin Jiang
Background: Bedaquiline (BDQ) has been designated as a Group A drug by the World Health Organization (WHO) for the management of multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). This systematic review and meta-analysis aim to evaluate the efficacy and safety of BDQ-containing regimens for the treatment of patients with pulmonary TB. Methods: PubMed (MEDLINE), Elton B. Stephens Company (EBSCO) database, the Cochrane Register of Controlled Trials, and the China National Knowledge Infrastructure (CNKI) database were initially searched on 15 June 2022 and again on 20 March 2023. We included randomized controlled trials (RCTs) and non-randomized studies (NRSs) that administered BDQ to TB patients. The outcomes of interest were as follows: (1) efficacy, including the rate of sputum culture conversion at 8 weeks, 24 weeks, and during follow-up, as well as the rates of completion cure, death, treatment failure, and loss at follow-up and at the end of the treatment; and (2) safety, which encompassed the incidences of cardiotoxicity, hepatotoxicity, and grade 3–5 adverse events during the treatment period. Results: A total of 29 articles were included in this meta-analysis, representing 23,358 individuals. Patients who were treated with BDQ were compared with patients who were not exposed to BDQ. The use of BDQ-containing regimens demonstrated improved rates of sputum conversion in RCTs at 24 weeks (RR = 1.27, 95% CI: 1.10 to 1.46) and during follow-up (RR = 1.33, 95% CI: 1.06 to 1.66). Additionally, BDQ-containing regimens showed increased cure rates (RR = 1.60, 95% CI: 1.13 to 2.26) and decreased failure rates (RR = 0.56, 95% CI: 0.56 to 0.88). In NRSs, BDQ-containing regimens improved the sputum culture conversion rate during follow-up (RR = 1.53, 95% CI: 1.07 to 2.20), increased the rate of cure (RR = 1.86, 95% CI: 1.23 to 2.83), reduced deaths from all causes (RR = 0.68, 95% CI: 0.48 to 0.97), and reduced failure rates (RR = 0.57, 95% CI: 0.46 to 0.71). However, the use of BDQ-containing regimens was associated with increased incidences of cardiotoxicity (RR = 4.54, 95% CI: 1.74 to 11.87) and grade 3–5 adverse events (RR = 1.42, 95% CI: 1.17 to 1.73) in RCTs. NRSs also showed an association between BDQ-containing regimens and cardiotoxicity (RR = 6.00, 95% CI: 1.32 to 27.19). No significant differences were observed between intervention groups and control groups with respect to other outcomes. Conclusions: Data from both RCTs and NRSs support the efficacy of BDQ for the treatment of pulmonary tuberculosis. However, the use of BDQ is associated with a higher incidence of cardiotoxicity and serious adverse events. Comparative data on efficacy and safety are limited, and further confirmation is required, due to potential bias and discrepancies in the available studies.

31 July 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
MZMingwu Zhang
Mingwu Zhang
YLYewei Lu
Yewei Lu
YZYelei Zhu
Yelei Zhu
KWKunyang Wu
Kunyang Wu
SCSonghua Chen
Songhua Chen
XWXiaomeng Wang
Xiaomeng Wang
Pulmonary tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB). Whole-genome sequencing (WGS) holds great promise as an advanced technology for accurately predicting anti-TB drug resistance. The development of a reliable method for detecting drug resistance is crucial in order to standardize anti-TB treatments, enhance patient prognosis, and effectively reduce the risk of transmission. In this study, our primary objective was to explore and determine the potential of WGS for assessing drug resistance based on genetic variants recommended by the World Health Organization (WHO). A total of 1105 MTB strains were selected from samples collected from 2014–2018 in Zhejiang Province, China. Phenotypic drug sensitivity tests (DST) of the anti-TB drugs were conducted for isoniazid (INH), rifampicin (RFP), streptomycin, ethambutol, fluoroquinolones (levofloxacin and moxifloxacin), amikacin, kanamycin, and capreomycin, and the drug-resistance rates were calculated. The clean WGS data of the 1105 strains were acquired and analyzed. The predictive performance of WGS was evaluated by the comparison between genotypic and phenotypic DST results. For all anti-TB drugs, WGS achieved good specificity values (>90%). The sensitivity values for INH and RFP were 91.78% and 82.26%, respectively; however, they were ≤60% for other drugs. The positive predictive values for anti-TB drugs were >80%, except for ethambutol and moxifloxacin, and the negative predictive values were >90% for all drugs. In light of the findings from our study, we draw the conclusion that WGS is a valuable tool for identifying genome-wide variants. Leveraging the genetic variants recommended by the WHO, WGS proves to be effective in detecting resistance to RFP and INH, enabling the identification of multi-drug resistant TB patients. However, it is evident that the genetic variants recommended for predicting resistance to other anti-TB drugs require further optimization and improvement.

1 June 2026 in Microbial Genomics
Verified
Journal Article
Open access
HCHaiting Chen
Haiting Chen
XLXiangchen Li
Xiangchen Li
RCRuiqi Chen
Ruiqi Chen
MZMingwu Zhang
Mingwu Zhang
YZYelei Zhu
Yelei Zhu
ZLZhengwei Liu
Zhengwei Liu
Background. The Mycobacterium tuberculosis H37Rv reference genome (Lineage 4), sequenced in 1998, may be incomplete and inaccurate due to earlier technology. Moreover, its use is problematic in regions like East Asia where the dominant Beijing lineage (Lineage 2) is prevalent, as it may introduce biases due to lineage-specific genetic differences. Methods. We performed hybrid sequencing to generate high-quality assemblies of a clinically isolated Beijing family strain (A2018772) and a Chinese laboratory-adapted H37Rv strain (H37Rv_CN). Comparative genomic analysis was conducted against the standard H37Rv reference. The impact of reference genome choice on transmission clustering was evaluated using a dataset of 3,359 M. tuberculosis Lineage 2 strains from China. Results. Comprehensive genomic analysis revealed substantial differences between both studied strains and H37Rv_ref. The Chinese laboratory-adapted H37Rv_CN strain differed by 145 SNPs, 49 InDels and 14 structural variants from the reference genome. The Beijing family clinical isolated strain A2018772 showed even greater divergence with 2,277 SNPs, 373 InDels and 219 structural variants compared to H37Rv_ref, with particular enrichment in PE/PPE genes and metabolic pathways. Among these variations, a 9.2 kb deletion was prevalent in 89.7% of 78 publicly available Lineage 2 genomes. When applied to transmission analysis of 3,359 Chinese Lineage 2 strains, the A2018772 as a reference genome demonstrated superior performance with higher mapping rates (99.52% vs. 98.72%) and coverage (99.73% vs. 98.50%) compared to H37Rv_ref. This improved resolution resulted in fewer transmission clusters (273 vs. 285) at the 5-SNP threshold, indicating that H37Rv_ref consistently overestimates transmission events in Lineage 2-dominated populations. Conclusion. Our study demonstrates the incompleteness of the H37Rv reference genome and also finds that using a lineage-specific reference genome could significantly improve transmission inference accuracy for Lineage 2 strains, highlighting the need for region-specific genomic references to enhance tuberculosis control strategies in high-burden areas.

13 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MZMingwu Zhang
Mingwu Zhang
YZYelei Zhu
Yelei Zhu
KWKunyang Wu
Kunyang Wu
RCRuiqi Chen
Ruiqi Chen
XWXiaomeng Wang
Xiaomeng Wang
JGJing Guo
Jing Guo
Objective The study aims to explore contributions of genetic variants located within inflammation regulation-related genes to PTB risk. Methods A case-control study including 168 smear-positive PTB cases and 251 controls was conducted. Nine genetic variants were selected and non-conditional logistic regression was conducted to estimate their contributions to PTB risk. Results Among the overall population, marginal significance was detected between rs2275913 and PTB risk (AG/AA vs. GG, OR=1.60,95%CI: 0.99-2.58, p=0.054). Among those aged < 60 years, rs3748067 was associated with reduced PTB risk (OR=0.25, 95% CI: 0.10-0.67, p=0.006) , while rs1800629 was associated with reduced PTB risk (OR=0.26, 95% CI: 0.07-0.95, p=0.042) among those aged ≥ 60 years. The SNPs including rs2275913(OR=2.06, 95%CI: 1.06-4.04, p=0.034) and rs3819024 (OR=2.04,95%CI:1.06-3.93,p=0.034) were associated with increased PTB risk among male population, while no significance was detected among female population. Haplotypes including GGCTGCAGC and GGCTGTGAC were associated with decreased PTB risk, while GGCTGCGAC and GGCTGTAGC were associated with increased risk. Conclusions Both rs3748067 and rs1800629 had potential to modify PTB risk together with age, while rs2275913 and rs3819024 might modify male PTB risk. Haplotypes composed of these SNPs were effective to predict PTB risk.